Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Highly Accessed Research article

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

Gerd R Burmester1*, Marco Matucci-Cerinic2, Xavier Mariette3, Francisco Navarro-Blasco4, Sonja Kary5, Kristina Unnebrink5 and Hartmut Kupper5

Author Affiliations

1 Department of Rheumatology and Clinical Immunology, Charité – University Medicine, Charitéplatz 1, 10117 Berlin, Germany

2 Azienda Ospedaliera Careggi, Largo Giovanni Alessandro Brambilla, 3, Firenze, Italy

3 Université Paris-Sud, AP-HP, Hôpital Bicêtre, INSERM U1012, 63, rue Gabriel Péri, Le Kremlin Bicêtre 94276, France

4 Hospital General, Universitario de Elche, Cami de L'Almassera, 11, 03203 Elche, Alicante, Spain

5 AbbVie Deutschland GmbH & Co KG, Knollstraße 50, 67061 Ludwigshafen, Germany

For all author emails, please log on.

Arthritis Research & Therapy 2014, 16:R24  doi:10.1186/ar4452

Published: 27 January 2014

Abstract

Introduction

Patients with active rheumatoid arthritis who had failed at least one disease-modifying anti-rheumatic drug (DMARD) were treated with adalimumab (ADA) in the ReAct study with the option to continue treatment for 5 years in ReAlise. The purpose of this study was to evaluate the long-term safety and effectiveness of ADA as prescribed from the first injection in ReAct to the last observation in ReAlise.

Methods

Patients received ADA alone or in combination with DMARDs according to usual clinical care practices. Adverse events (AEs) were tabulated by five time windows after the first ADA injection. Effectiveness measures included achievement of low disease activity (LDA), defined as Simplified Disease Activity Index (SDAI) ≤11, or remission, (REM), defined as SDAI ≤3.3.

Results

Of the 6,610 ReAct patients, 3,435 (52%) continued in ReAlise. At baseline in ReAct, mean age was 54 years, mean DAS28 was 6.0 and mean HAQ DI was 1.64. The mean treatment duration was 1,016 days, representing 18,272 patient-years (PYs) of ADA exposure. Overall incidence rates of serious AEs and serious infections were 13.8 and 2.8 events (E)/100 PYs, respectively. Serious AEs occurred most frequently in the first 6 months and deceased thereafter. Standardised mortality ratio was 0.71 (95% CI 0.57 to 0.87) and standardised incidence ratio for malignancies was 0.64 (95% CI 0.53 to 0.76). LDA was achieved by 50% and REM by 21% of patients at last observation.

Conclusions

Results of this large observational study of ADA in routine clinical practice were consistent with controlled trials, with no new safety concerns during a follow-up of more than 5 years. Effectiveness of ADA was maintained during long-term observation.

Trial registration

NCT00448383, NCT00234884